诊所办公室/实验室的分散测试和服务趋势和增长指标

COVID-19 加速了创新，技术先进的便携式网络连接加密设备可在几分钟内提供结果，正在改变诊断医学行业。 分散式检测使临床医生能够为患者做出挽救生命的决定，减少供应链滞后，降低现场实验室检测成本，缩短住院时间和排队时间，减少和改善农村地区及时医疗干预的机会。

本报告审视了分布式测试和服务的趋势，提供了市场概况/背景、分布式测试和服务的主要趋势、增长动力/限制因素、监管环境、商业模式和增长机会。它总结了对

内容

战略要务

• 增长问题
• 战略要务 8 (TM)
• 三大战略要务的影响
• 增长机会推动增长PipelineEngine (TM)

增长机会分析

• 分析范围
• 分类
• 分布式检查和服务的主要趋势
• 增长动力
• 抑制增长的因素
• 主要监管趋势：美国
• 主要监管趋势：欧洲/英国
• 主要监管政策的影响

商业模式/竞争环境

• 随时随地互联健康
• 竞争格局

增长机会领域

• 增长机会：新检查站的 DaaS（诊断即服务）
• 增长机会：智能家居诊所
• 增长机会：农村医疗保健中由药剂师主导的诊断□□服务
• 成长机会：可预防性失明的视网膜诊断

附录

Personalized Diagnostics Are at the Cusp of Transformational Growth

Accelerated reforms due to COVID-19 and technologically advanced sample-in-answer-out portable, web-connected, encrypted devices that provide results in a few minutes changed the diagnostic healthcare industry. Decentralized testing empowers clinicians to make lifesaving decisions for the patient. It shortens supply chain lag time, saves costs of in-person clinical examination, reduces the length of hospital stay and wait lines, and helps improve access to rural and semi-urban settings for timely healthcare intervention.

The next-generation point-of-care diagnostics is at an inflection point and is transforming patient care in emergency, acute, chronic, and specialized care with platforms capable of monitoring/measuring a wide range of disease markers with laboratory precision. The diagnostic innovation of assays for rapid detection, miniaturization of portable devices, and automation of workflows serves the broad spectrum of setting and shift toward hyper-scaling of access and comprehensive test designs.

The study showcases several diagnostic technologies, such as a microfluidic-based hand-held portable device (lab-on-a-chip device) designed to provide atraumatic, end-to-end point-of-care automated and integrated diagnostic solution, with its sample-on-chip preparation and nucleic acid analysis assay.

• The recent paper-based devices with Nucleic Acid Testing (NAT) have shown great promise for infectious diseases and detection etiology of infection (bacterial, viral, or fungal) with its cost-effective, bio-compatible, disposable on-site monitoring/testing.

• Lateral flow devices with sensor technology enable rapid analysis of blood samples for many critical care assays. These include blood gases/electrolytes, cardiac markers, cholesterol/lipids, coagulation monitoring, glucose monitoring, hematology, infectious diseases, pregnancy and fertility, tumor/cancer markers, urinalysis, other chemistries (magnesium, lactate, micro-albumin, creatinine), and more.

• Decentralized clinical diagnostics continue to innovate a wide range of systems and assays with rapid test analyzers, instruments, reagents, strips, and cartridges. The electronic services complement it with automation, cloud computing, and deep learning for rapid and accurate results.

Digital technology is accelerating the adoption of decentralization in clinical practice as the workflows integrate with POC at-home systems delivering lab results on smartphones. Integrated, comprehensive diagnostic services are key differentiators for stakeholders, which vary in their offering to enterprises (labs, physician offices, or hospital emergency units) or patients. These services will enhance patient-centered access to care and help physicians close the diagnostic loop of the healthcare continuum.

The regulatory environment analysis of the study provides insight into policies in the US, Europe, and the UK that are currently shaping the implementation of decentralized clinical diagnostics and influencing market adoption.

The study, with an in-depth analysis of the industry environment and its participants, such as clinical laboratories, diagnostic/technology companies, retail, pharmacies, and start-ups, proposes a market model for connected healthcare and the prospective growth opportunities for stakeholders.

Frost & Sullivan predicts the decentralized diagnostic testing market and services to grow exponentially in the next 5 years. This forecast considers structural shifts and economic uncertainties, rising costs, decreasing volumes of COVID-19 tests, government regulations encouraging decentralized care adoption, the discovery of critical assays augmented with AI automation, digital integration, participation of nontraditional players in technology and retail, and more.

Key Issues Addressed:

• Which critical strategic imperatives influence the US, Europe, and the UK's diagnostic testing and service market?

• What are the regulatory trends in the US, Europe, and the UK and their impact on the decentralized testing and service market?

• What are the key segments, trends, market drivers, and restraints?

• What is the new business model and its applications?

• What is the decentralized testing and service market and the competitive landscape?

• What are the key growth opportunities?

Table of Contents

Strategic Imperatives

• Why is it Increasingly Difficult to Grow?
• The Strategic Imperative 8™
• The Impact of the Top 3 Strategic Imperatives on Decentralized Testing and Service Market
• Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

• Scope of Analysis
• Segmentation
• Key Trends in Decentralized Testing and Services
• Key Trends in Decentralized Testing and Services (continued)
• Growth Drivers
• Growth Restraints
• Key Regulatory Trends-US
• Key Regulatory Trends-Europe-UK
• Key Regulatory Policy Impact

Business Model and Competitive Environment

• Connected Health Everywhere
• Competitive Landscape*

Growth Opportunity Universe

• Growth Opportunity 1: Diagnostics as a Service in Newer Testing Sites
• Growth Opportunity 1: Diagnostics as a Service in Newer Testing Sites (continued)
• Growth Opportunity 2: Home-as-a-Smart Clinic
• Growth Opportunity 2: Home-as-a-Smart Clinic (continued)
• Growth Opportunity 3: Pharmacist-led Diagnostic Services in Rural Health Care
• Growth Opportunity 3: Pharmacist-led Diagnostic Services in Rural Health Care (continued)
• Growth Opportunity 4: Retinal Diagnostics in Preventable Blindness
• Growth Opportunity 4: Retinal Diagnostics in Preventable Blindness (continued)

Appendix

• Abbreviations
• Abbreviations (continued)
• Abbreviations (continued)
• List of Exhibits
• Legal Disclaimer